Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 228 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: N-acetyl-cysteine Clear all
Completed Phase 2 Interventional

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

NCT01320527
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nutriceutical formulation, Placebo
Dietary Supplement · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oxidative Pathways in MS Fatigue

NCT02804594
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Fatigue
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia

NCT04594733
View directory record Official record
Conditions
Fibromyalgia
Interventions
minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo, Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 17, 2026, 10:29 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Clinical Trial for CTD-ILD Treatment

NCT01424033
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Disease
Interventions
N-Acetylcysteine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy in RYR1-Related Congenital Myopathy

NCT02362425
View directory record Official record
Conditions
Neuromuscular Disease
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
7 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 17, 2026, 10:29 AM EDT
Not listed Phase 4 Interventional

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

NCT00939913
View directory record Official record
Conditions
Nephropathy
Interventions
intravenous NAC, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Sep 17, 2026, 10:29 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 17, 2026, 10:29 AM EDT
Not listed Not applicable Interventional

N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring

NCT02865629
View directory record Official record
Conditions
Depression
Interventions
N-acetyl cysteine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 17, 2026, 10:29 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Inhaled NAC in Treatment of IPF

NCT03720483
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
N-acetyl cysteine then Placebo, Placebo then N-acetyl cysteine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

NCT01840345
View directory record Official record
Conditions
Neuropathic Pain
Interventions
N-acetyl-l-cysteine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 17, 2026, 10:29 AM EDT
Active, not recruiting Not applicable Interventional

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

NCT06311045
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy
Dietary Supplement · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 17, 2026, 10:29 AM EDT
Not listed Not applicable Interventional

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

NCT04117022
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
DVS supplementation
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pomona, California • Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 17, 2026, 10:29 AM EDT
Terminated Phase 2Phase 3 Interventional

N-acetylcysteine in Bulimia Nervosa

NCT01131572
View directory record Official record
Conditions
NAC
Interventions
N-acetylcysteine NAC
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 17, 2026, 10:29 AM EDT
Withdrawn Early Phase 1 Interventional

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

NCT05371288
View directory record Official record
Conditions
COVID-19
Interventions
NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

NCT01427517
View directory record Official record
Conditions
Parkinson's Disease, Gaucher's Disease
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 1 Interventional

The FIGHT-RP1 Study

NCT03063021
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2022 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

NCT00650091
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 17, 2026, 10:29 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

NCT05494398
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N-acetylcysteine
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 13 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645
View directory record Official record
Conditions
Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions
low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine
Other · Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

NCT02791945
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
Interventions
Medical Management Counseling, N-acetylcysteine, Placebo
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 17, 2026, 10:29 AM EDT
Active, not recruiting Phase 4 Interventional

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

NCT06152653
View directory record Official record
Conditions
Asthma, COPD
Interventions
n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Not applicable Interventional

The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease

NCT00498342
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Sep 17, 2026, 10:29 AM EDT
Completed Early Phase 1 Interventional Results available

NAC +taVNS in IDM Who Are Poor Oral Feeders

NCT04632069
View directory record Official record
Conditions
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
Interventions
N acetyl cysteine + vagus nerve stimulation
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Weeks to 5 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 17, 2026, 10:29 AM EDT